[S02DA03, antipyrine, The metabolism of Olodaterol can be decreased when combined with Antipyrine.]
[J01EC02, sulfadiazine, The metabolism of Olodaterol can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Olodaterol can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Olodaterol.]
[J01EC03, sulfamoxole, The metabolism of Olodaterol can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Olodaterol can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Olodaterol can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Olodaterol can be decreased when combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Olodaterol.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Sulpiride.]
[A10BB04, glibornuride, The metabolism of Olodaterol can be decreased when combined with Glibornuride.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Azapropazone is combined with Olodaterol.]
[L01BB02, mercaptopurine, Mercaptopurine may increase the hyperkalemic activities of Olodaterol.]
[L02BA01, tamoxifen, The metabolism of Olodaterol can be decreased when combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Olodaterol can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Olodaterol.]
[G03BA03, testosterone, The metabolism of Olodaterol can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Olodaterol.]
[A04AD10, dronabinol, The metabolism of Olodaterol can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Olodaterol.]
[L04AX02, thalidomide, The metabolism of Olodaterol can be decreased when combined with Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the hyperkalemic activities of Olodaterol.]
[R03DA04, theophylline, Theophylline may increase the hyperkalemic activities of Olodaterol.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Olodaterol.]
[N05AB08, thioproperazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Olodaterol.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Olodaterol is combined with Moxisylyte.]
[B01AC05, ticlopidine, The metabolism of Olodaterol can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, Timolol may decrease the bronchodilatory activities of Olodaterol.]
[A10BB05, tolazamide, The metabolism of Olodaterol can be decreased when combined with Tolazamide.]
[M02AX02, tolazoline, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Olodaterol can be decreased when combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Olodaterol.]
[N02AX02, tramadol, The risk or severity of Tachycardia can be increased when Tramadol is combined with Olodaterol.]
[N06AF04, tranylcypromine, The metabolism of Olodaterol can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Olodaterol.]
[L01XF01, tretinoin, The metabolism of Olodaterol can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Olodaterol.]
[C03AA06, trichlormethiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Mepenzolate is combined with Olodaterol.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Trifluoperazine.]
[N05AA05, triflupromazine, The risk or severity of Tachycardia can be increased when Triflupromazine is combined with Olodaterol.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Olodaterol.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Olodaterol.]
[R03BA07, mometasone, The risk or severity of hypokalemia can be increased when Mometasone is combined with Olodaterol.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Olodaterol.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Olodaterol.]
[C02BA01, trimethaphan, Olodaterol may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Olodaterol can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Olodaterol.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Vilazodone is combined with Olodaterol.]
[C09CA09, azilsartan medoxomil, Olodaterol may decrease the antihypertensive activities of Azilsartan medoxomil.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Olodaterol can be decreased when combined with Abiraterone.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Olodaterol.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Olodaterol.]
[R03AC18, indacaterol, The risk or severity of adverse effects can be increased when Indacaterol is combined with Olodaterol.]
[B01AC24, ticagrelor, The metabolism of Olodaterol can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Verapamil.]
[C04AX07, vincamine, Olodaterol may decrease the antihypertensive activities of Vincamine.]
[B01AA03, warfarin, The metabolism of Olodaterol can be increased when combined with Warfarin.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Olodaterol is combined with Xenon.]
[C03BA10, xipamide, Olodaterol may decrease the antihypertensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Olodaterol can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Vemurafenib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Olodaterol can be decreased when combined with Zafirlukast.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Olodaterol.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Olodaterol.]
[L01EJ01, ruxolitinib, The metabolism of Olodaterol can be decreased when combined with Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Olodaterol.]
[C07AB03, atenolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Atenolol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Olodaterol.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atropine is combined with Olodaterol.]
[L01XJ01, vismodegib, The metabolism of Olodaterol can be decreased when combined with Vismodegib.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Olodaterol.]
[G04BE10, avanafil, The metabolism of Olodaterol can be decreased when combined with Avanafil.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Olodaterol.]
[L02BB04, enzalutamide, The serum concentration of Olodaterol can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Olodaterol can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The metabolism of Olodaterol can be decreased when combined with Teriflunomide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Olodaterol is combined with Octopamine.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Olodaterol.]
[L01EX05, regorafenib, The metabolism of Olodaterol can be decreased when combined with Regorafenib.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Olodaterol.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Rasagiline is combined with Olodaterol.]
[C08CA13, lercanidipine, Olodaterol may decrease the antihypertensive activities of Lercanidipine.]
[N06DA02, donepezil, The metabolism of Olodaterol can be decreased when combined with Donepezil.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Olodaterol.]
[R06AC06, thonzylamine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of Tachycardia can be increased when Darifenacin is combined with Olodaterol.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Olodaterol is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Olodaterol can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Olodaterol.]
[G04BE03, sildenafil, The metabolism of Olodaterol can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Olodaterol.]
[B01AF02, apixaban, The metabolism of Olodaterol can be decreased when combined with Apixaban.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Bendroflumethiazide.]
[G03XC05, ospemifene, The metabolism of Olodaterol can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Olodaterol is combined with Benorilate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Olodaterol can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Olodaterol can be decreased when combined with Tegaserod.]
[M01AH01, celecoxib, The metabolism of Olodaterol can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Naratriptan is combined with Olodaterol.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Olodaterol.]
[L01EC02, dabrafenib, The serum concentration of Olodaterol can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Olodaterol is combined with Benzydamine.]
[L01EE01, trametinib, The metabolism of Olodaterol can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Olodaterol can be decreased when combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the tachycardic activities of Olodaterol.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Olodaterol can be decreased when combined with Riociguat.]
[C02KX04, macitentan, Olodaterol may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The metabolism of Olodaterol can be decreased when combined with Vortioxetine.]
[A10BK01, dapagliflozin, The metabolism of Olodaterol can be decreased when combined with Dapagliflozin.]
[C01CA27, droxidopa, The risk or severity of adverse effects can be increased when Droxidopa is combined with Olodaterol.]
[C07AB04, acebutolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Acebutolol.]
[L04AA32, apremilast, The metabolism of Olodaterol can be increased when combined with Apremilast.]
[N07CA01, betahistine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Betahistine.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Olodaterol.]
[S01ED02, betaxolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Betaxolol.]
[C02CC01, bethanidine, Olodaterol may decrease the antihypertensive activities of Bethanidine.]
[C10AB02, bezafibrate, The metabolism of Olodaterol can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Olodaterol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Olodaterol can be decreased when combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Olodaterol.]
[B01AA07, acenocoumarol, The metabolism of Olodaterol can be decreased when combined with Acenocoumarol.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Pipemidic acid.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Olodaterol.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Olodaterol can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Acepromazine.]
[V04CX03, methacholine, Olodaterol may decrease effectiveness of Methacholine as a diagnostic agent.]
[N04AA02, biperiden, The risk or severity of Tachycardia can be increased when Biperiden is combined with Olodaterol.]
[L04AX05, pirfenidone, The metabolism of Olodaterol can be decreased when combined with Pirfenidone.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Olodaterol.]
[B01AA01, dicumarol, The metabolism of Olodaterol can be decreased when combined with Dicoumarol.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Olodaterol.]
[L04AC10, secukinumab, The metabolism of Olodaterol can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Panobinostat.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Olodaterol.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Flibanserin is combined with Olodaterol.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Cariprazine is combined with Olodaterol.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Aceclofenac is combined with Olodaterol.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Olodaterol is combined with Acemetacin.]
[A02BC03, lansoprazole, The metabolism of Olodaterol can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Olodaterol can be decreased when combined with Trabectedin.]
[J02AC05, isavuconazole, The metabolism of Olodaterol can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Olodaterol.]
[A10BB31, acetohexamide, The metabolism of Olodaterol can be decreased when combined with Acetohexamide.]
[G04CA01, alfuzosin, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Alfuzosin.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Olodaterol.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Olodaterol is combined with Alminoprofen.]
[N03AX23, brivaracetam, The metabolism of Olodaterol can be decreased when combined with Brivaracetam.]
[N04BC01, bromocriptine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Olodaterol.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Amineptine is combined with Olodaterol.]
[C08CA01, amlodipine, Olodaterol may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Bumetanide.]
[C07AA19, bupranolol, Bupranolol may decrease the bronchodilatory activities of Olodaterol.]
[N07BC01, buprenorphine, The metabolism of Olodaterol can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Olodaterol.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Buspirone is combined with Olodaterol.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Olodaterol.]
[S01GX07, azelastine, The metabolism of Olodaterol can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Olodaterol can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Balsalazide is combined with Olodaterol.]
[R03CC12, bambuterol, The risk or severity of adverse effects can be increased when Bambuterol is combined with Olodaterol.]
[R03DA08, bamifylline, Bamifylline may increase the hyperkalemic activities of Olodaterol.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Olodaterol.]
[N06BC01, caffeine, Caffeine may increase the hyperkalemic activities of Olodaterol.]
[C09AA07, benazepril, Olodaterol may decrease the antihypertensive activities of Benazepril.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Olodaterol.]
[L04AB02, infliximab, The metabolism of Olodaterol can be increased when combined with Infliximab.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Olodaterol.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Safinamide is combined with Olodaterol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Delafloxacin.]
[L01BC06, capecitabine, The metabolism of Olodaterol can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Olodaterol.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Olodaterol.]
[C07AB07, bisoprolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of adverse effects can be increased when Bitolterol is combined with Olodaterol.]
[J05AG03, efavirenz, The metabolism of Olodaterol can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may decrease the bronchodilatory activities of Olodaterol.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Bornaprine.]
[R03BA02, budesonide, The risk or severity of hypokalemia can be increased when Budesonide is combined with Olodaterol.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Olodaterol is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Olodaterol is combined with Bumadizone.]
[J05AX18, letermovir, The metabolism of Olodaterol can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Butriptyline is combined with Olodaterol.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Acetyldigoxin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Acrivastine.]
[C09AA01, captopril, Olodaterol may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Olodaterol.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Carbinoxamine.]
[C07AG02, carvedilol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Olodaterol can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Olodaterol can be increased when combined with Avatrombopag.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Encorafenib.]
[C07AB08, celiprolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Olodaterol.]
[L01XX62, ivosidenib, The metabolism of Olodaterol can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Olodaterol can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Olodaterol can be increased when combined with Tecovirimat.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Olodaterol.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Olodaterol.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Olodaterol.]
[R06AA06, chlorphenoxamine, The risk or severity of Tachycardia can be increased when Chlorphenoxamine is combined with Olodaterol.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Lornoxicam is combined with Olodaterol.]
[R03DA02, oxtriphylline, Oxtriphylline may increase the hyperkalemic activities of Olodaterol.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Inotersen.]
[L04AA39, emapalumab, The metabolism of Olodaterol can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Cibenzoline.]
[C09AA08, cilazapril, Olodaterol may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Olodaterol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Cinitapride is combined with Olodaterol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Olodaterol.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Olodaterol is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Olodaterol.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Olodaterol.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Olodaterol.]
[C09CA06, candesartan, The metabolism of Olodaterol can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Olodaterol can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Olodaterol.]
[L01EM03, alpelisib, The serum concentration of Olodaterol can be decreased when it is combined with Alpelisib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Cicletanine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Entrectinib.]
[N07XX11, pitolisant, Olodaterol may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Olodaterol.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Olodaterol.]
[C03AA09, cyclothiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Yohimbine is combined with Olodaterol.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Olodaterol.]
[G03AC09, desogestrel, The metabolism of Olodaterol can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Olodaterol.]
[N03AX25, cenobamate, The metabolism of Olodaterol can be increased when combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Olodaterol.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Dexchlorpheniramine.]
[L01EX18, avapritinib, The metabolism of Olodaterol can be decreased when combined with Avapritinib.]
[M01AX21, diacetylrhein, The metabolism of Olodaterol can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Olodaterol.]
[J05AE05, amprenavir, The metabolism of Olodaterol can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Frovatriptan is combined with Olodaterol.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Olodaterol.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Olodaterol.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Olodaterol.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Olodaterol.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Olodaterol.]
[L01XF03, bexarotene, The metabolism of Olodaterol can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Olodaterol can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Olodaterol.]
[C02AA06, methoserpidine, Olodaterol may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Olodaterol.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Olodaterol is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Olodaterol.]
[G04BD09, trospium, The risk or severity of Tachycardia can be increased when Trospium is combined with Olodaterol.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Olodaterol is combined with Droxicam.]
[L01EX22, selpercatinib, The serum concentration of Olodaterol can be increased when it is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Olodaterol is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Olodaterol may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Olodaterol can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Olodaterol can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Olodaterol can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Olodaterol can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Olodaterol can be decreased when combined with Chlorpropamide.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Olodaterol.]
[C03BA04, chlorthalidone, Olodaterol may decrease the antihypertensive activities of Chlorthalidone.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Olodaterol is combined with Ethenzamide.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Olodaterol.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Etofenamate is combined with Olodaterol.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Olodaterol can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Relugolix.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Olodaterol is combined with Naxitamab.]
[L01EX21, tepotinib, The metabolism of Olodaterol can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Olodaterol can be decreased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Fenbufen is combined with Olodaterol.]
[N06BA10, fenethylline, Fenethylline may increase the hyperkalemic activities of Olodaterol.]
[C01CA19, fenoldopam, Olodaterol may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Olodaterol is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Finasteride is combined with Olodaterol.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Olodaterol.]
[R03BA03, flunisolide, The risk or severity of hypokalemia can be increased when Flunisolide is combined with Olodaterol.]
[S02BA08, fluocinolone acetonide, The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Olodaterol.]
[R03CC15, formoterol, Olodaterol may increase the sympathomimetic activities of Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Olodaterol.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Olodaterol is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Olodaterol can be increased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Olodaterol may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Olodaterol can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Citalopram.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Olodaterol.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Olodaterol is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Olodaterol.]
[A10BB12, glimepiride, The metabolism of Olodaterol can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Olodaterol can be decreased when combined with Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of adverse effects can be increased when Clenbuterol is combined with Olodaterol.]
[L01EA06, asciminib, The metabolism of Olodaterol can be decreased when combined with Asciminib.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Olodaterol.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Olodaterol.]
[B06AX04, mitapivat, The metabolism of Olodaterol can be increased when combined with Mitapivat.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of hypertension can be increased when Clomipramine is combined with Olodaterol.]
[S01EA04, clonidine, Olodaterol may decrease the antihypertensive activities of Clonidine.]
[C01EB24, mavacamten, The serum concentration of Olodaterol can be decreased when it is combined with Mavacamten.]
[H01CC04, linzagolix, The serum concentration of Olodaterol can be increased when it is combined with Linzagolix.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Granisetron.]
[N05AH02, clozapine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Clozapine.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Cocaine.]
[C02KB01, metyrosine, Olodaterol may decrease the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Olodaterol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Olodaterol is combined with Proquazone.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Hexocyclium is combined with Olodaterol.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Olodaterol.]
[L04AA13, leflunomide, The metabolism of Olodaterol can be decreased when combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Olodaterol.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Ifenprodil is combined with Olodaterol.]
[A10BX03, nateglinide, The metabolism of Olodaterol can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Olodaterol is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Olodaterol.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Olodaterol is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Olodaterol.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Isometheptene is combined with Olodaterol.]
[N02CC05, almotriptan, The metabolism of Olodaterol can be decreased when combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Parecoxib is combined with Olodaterol.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Olodaterol.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Emedastine.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Kebuzone is combined with Olodaterol.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Olodaterol.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Olodaterol.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Olodaterol.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Olodaterol.]
[N07BC04, lofexidine, Olodaterol may decrease the antihypertensive activities of Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Olodaterol is combined with Lonazolac.]
[R06AX13, loratadine, The metabolism of Olodaterol can be decreased when combined with Loratadine.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Olodaterol is combined with Loxoprofen.]
[C09AA03, lisinopril, Olodaterol may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Olodaterol can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Olodaterol is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may decrease the bronchodilatory activities of Olodaterol.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Olodaterol.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Olodaterol.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Metixene is combined with Olodaterol.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Olodaterol is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Olodaterol.]
[C03DA04, eplerenone, Olodaterol may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Melperone.]
[C03AA07, cyclopenthiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The metabolism of Olodaterol can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, The risk or severity of hypertension can be increased when Minaprine is combined with Olodaterol.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Olodaterol.]
[N06AG02, moclobemide, The risk or severity of hypertension can be increased when Moclobemide is combined with Olodaterol.]
[N06BA07, modafinil, The metabolism of Olodaterol can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Olodaterol.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Olodaterol.]
[C10AA07, rosuvastatin, The metabolism of Olodaterol can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Olodaterol is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Olodaterol is combined with Morniflumate.]
[C02AC05, moxonidine, Olodaterol may decrease the antihypertensive activities of Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Olodaterol.]
[M01AH05, etoricoxib, The metabolism of Olodaterol can be decreased when combined with Etoricoxib.]
[J04BA02, dapsone, The metabolism of Olodaterol can be decreased when combined with Dapsone.]
[C02CC04, debrisoquin, Olodaterol may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The metabolism of Olodaterol can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Olodaterol.]
[C07AB12, nebivolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Nebivolol.]
[N06AX06, nefazodone, Nefazodone may increase the tachycardic activities of Olodaterol.]
[C01DX16, nicorandil, Olodaterol may decrease the antihypertensive activities of Nicorandil.]
[L02BB02, nilutamide, The metabolism of Olodaterol can be decreased when combined with Nilutamide.]
[C01CA23, theodrenaline, Theodrenaline may increase the hyperkalemic activities of Olodaterol.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Olodaterol is combined with Norfenefrine.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Olodaterol.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Olsalazine is combined with Olodaterol.]
[N06AA01, desipramine, The risk or severity of hypertension can be increased when Desipramine is combined with Olodaterol.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Olodaterol.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Olodaterol.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Olodaterol.]
[C09XA02, aliskiren, Olodaterol may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Olodaterol.]
[S03BA01, dexamethasone, The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Olodaterol.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Dexetimide is combined with Olodaterol.]
[G04BD04, oxybutynin, The metabolism of Olodaterol can be decreased when combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Olodaterol.]
[L04AB04, adalimumab, The metabolism of Olodaterol can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Olodaterol.]
[R05DA09, dextromethorphan, The metabolism of Olodaterol can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Olodaterol can be decreased when combined with Paramethadione.]
[N06AB05, paroxetine, The metabolism of Olodaterol can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Olodaterol can be decreased when combined with Clopidogrel.]
[C04AD01, pentifylline, Pentifylline may increase the hyperkalemic activities of Olodaterol.]
[N05BA01, diazepam, The metabolism of Olodaterol can be decreased when combined with Diazepam.]
[V03AH01, diazoxide, Olodaterol may decrease the antihypertensive activities of Diazoxide.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Dibenzepin is combined with Olodaterol.]
[S01BC03, diclofenac, The metabolism of Olodaterol can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Olodaterol.]
[A03AA07, dicyclomine, The risk or severity of Tachycardia can be increased when Dicyclomine is combined with Olodaterol.]
[C02DG01, pinacidil, Olodaterol may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Pinaverium.]
[A10BG03, pioglitazone, The metabolism of Olodaterol can be decreased when combined with Pioglitazone.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Olodaterol.]
[R03CC07, pirbuterol, The risk or severity of adverse effects can be increased when Pirbuterol is combined with Olodaterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Piretanide.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Diethylpropion is combined with Olodaterol.]
[L02AA01, diethylstilbestrol, The metabolism of Olodaterol can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Olodaterol.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Olodaterol.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Olodaterol.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Olodaterol.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Olodaterol.]
[C02DB01, dihydralazine, Olodaterol may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[N02AA03, hydromorphone, The metabolism of Olodaterol can be decreased when combined with Hydromorphone.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Olodaterol.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Olodaterol.]
[C08DB01, diltiazem, The metabolism of Olodaterol can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Dimenhydrinate.]
[R06AB03, dimethindene, The risk or severity of Tachycardia can be increased when Dimetindene is combined with Olodaterol.]
[R03CC08, procaterol, The risk or severity of adverse effects can be increased when Procaterol is combined with Olodaterol.]
[N06BC02, propentofylline, Propentofylline may increase the hyperkalemic activities of Olodaterol.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Olodaterol is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Olodaterol is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Olodaterol can be decreased when combined with Diosmin.]
[R03DA03, proxyphylline, Proxyphylline may increase the hyperkalemic activities of Olodaterol.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Olodaterol.]
[N05CD10, quazepam, The metabolism of Olodaterol can be decreased when combined with Quazepam.]
[C09AA06, quinapril, Olodaterol may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Dexmethylphenidate is combined with Olodaterol.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Quinupramine is combined with Olodaterol.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Cisapride.]
[C09AA05, ramipril, Olodaterol may decrease the antihypertensive activities of Ramipril.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Olodaterol is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Olodaterol.]
[S02AA12, rifamycin SV, The metabolism of Olodaterol can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Olodaterol can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Olodaterol.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Olodaterol.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Olodaterol.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Olodaterol.]
[G04BE08, tadalafil, Olodaterol may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The metabolism of Olodaterol can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, Olodaterol may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Salsalate is combined with Olodaterol.]
[R03AC12, salmeterol, The metabolism of Olodaterol can be decreased when combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Dobutamine is combined with Olodaterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Olodaterol.]
[N06AA16, dothiepin, The risk or severity of hypertension can be increased when Dosulepin is combined with Olodaterol.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Olodaterol.]
[N06AA12, doxepin, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Doxepin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Olodaterol.]
[N06AB06, sertraline, The metabolism of Olodaterol can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Olodaterol.]
[N05AD08, droperidol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Droperidol.]
[A08AA10, sibutramine, Sibutramine may increase the tachycardic activities of Olodaterol.]
[C10AA01, simvastatin, The metabolism of Olodaterol can be decreased when combined with Simvastatin.]
[C09AA11, spirapril, Olodaterol may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, Dyphylline may increase the hyperkalemic activities of Olodaterol.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Olodaterol.]
[C07AB13, talinolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Olodaterol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Olodaterol.]
[G04CA03, terazosin, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Terazosin.]
[D01BA02, terbinafine, The metabolism of Olodaterol can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may decrease the bronchodilatory activities of Olodaterol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Tetryzoline is combined with Olodaterol.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Emepronium.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Tianeptine is combined with Olodaterol.]
[C09AA02, enalapril, Olodaterol may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Olodaterol is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Olodaterol is combined with Toloxatone.]
[N06BA09, atomoxetine, Atomoxetine may increase the tachycardic activities of Olodaterol.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Olodaterol is combined with Tramazoline.]
[C09AA10, trandolapril, Olodaterol may decrease the antihypertensive activities of Trandolapril.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Olodaterol.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Olodaterol.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Olodaterol.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Olodaterol is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Olodaterol.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Ephedrine is combined with Olodaterol.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Olodaterol.]
[N06AX16, venlafaxine, Venlafaxine may increase the tachycardic activities of Olodaterol.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Olodaterol is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Xylometazoline is combined with Olodaterol.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Epinephrine is combined with Olodaterol.]
[C09AA15, zofenopril, Olodaterol may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Olodaterol can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Zomepirac is combined with Olodaterol.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Olodaterol.]
[N05CF01, zopiclone, The metabolism of Olodaterol can be decreased when combined with Zopiclone.]
[C02AC02, guanfacine, Olodaterol may decrease the antihypertensive activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Olodaterol.]
[G02AB03, ergonovine, Ergometrine may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[N02CA02, ergotamine, Ergotamine may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Erythromycin.]
[G03CA03, estradiol, The metabolism of Olodaterol can be decreased when combined with Estradiol.]
[J04AK02, ethambutol, The metabolism of Olodaterol can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Olodaterol can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Olodaterol can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Olodaterol can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Olodaterol is combined with Gepefrine.]
[L02AA03, ethinyl estradiol, The metabolism of Olodaterol can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ibutilide.]
[N04AA05, profenamine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Profenamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Olodaterol.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Olodaterol.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Etilefrine is combined with Olodaterol.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Olodaterol.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Olodaterol.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Olodaterol.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Olodaterol.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Olodaterol can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Olodaterol can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Olodaterol.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Olodaterol.]
[C08CA02, felodipine, The metabolism of Olodaterol can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Olodaterol.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Olodaterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Fentanyl is combined with Olodaterol.]
[R03CC02, albuterol, The risk or severity of adverse effects can be increased when Salbutamol is combined with Olodaterol.]
[G04BD02, flavoxate, The risk or severity of Tachycardia can be increased when Flavoxate is combined with Olodaterol.]
[C01BC04, flecainide, The metabolism of Olodaterol can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Floctafenine is combined with Olodaterol.]
[J02AC01, fluconazole, The metabolism of Olodaterol can be decreased when combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Olodaterol.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Olodaterol.]
[N07CA03, flunarizine, The metabolism of Olodaterol can be decreased when combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Olodaterol can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Olodaterol.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Melitracen is combined with Olodaterol.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Olodaterol.]
[V03AZ01, ethanol, The metabolism of Olodaterol can be decreased when combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Olodaterol can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Olodaterol.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Olodaterol.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Olodaterol.]
[N05AF01, flupenthixol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Flupentixol.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Olodaterol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Fluspirilene.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Olodaterol.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Adrafinil is combined with Olodaterol.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Furazolidone is combined with Olodaterol.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Furosemide.]
[N05CF04, eszopiclone, The metabolism of Olodaterol can be decreased when combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Olodaterol.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Olodaterol.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Gallopamil.]
[C10AB04, gemfibrozil, The metabolism of Olodaterol can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Olodaterol.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Olodaterol.]
[N04BC06, cabergoline, Cabergoline may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[C01CA21, cafedrine, Cafedrine may increase the hyperkalemic activities of Olodaterol.]
[J05AG04, etravirine, The metabolism of Olodaterol can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Olodaterol.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Alfentanil is combined with Olodaterol.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Olodaterol.]
[A10BB01, glyburide, The metabolism of Olodaterol can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Olodaterol can be decreased when combined with Gliclazide.]
[A10BB07, glipizide, The metabolism of Olodaterol can be decreased when combined with Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Olodaterol.]
[C05AE01, nitroglycerin, Olodaterol may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Dofetilide.]
[C02CA04, doxazosin, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Olodaterol.]
[C07AB09, esmolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Esmolol.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Olodaterol.]
[C09AA09, fosinopril, Olodaterol may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Olodaterol may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Halothane is combined with Olodaterol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Olodaterol.]
[N05AH04, quetiapine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Quetiapine.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Olodaterol.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Olodaterol.]
[N05CA16, hexobarbital, The metabolism of Olodaterol can be decreased when combined with Hexobarbital.]
[R03CC05, hexoprenaline, The risk or severity of adverse effects can be increased when Hexoprenaline is combined with Olodaterol.]
[J05AG01, nevirapine, The metabolism of Olodaterol can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Olodaterol can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Nimesulide is combined with Olodaterol.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Oxatomide.]
[C09AA04, perindopril, Olodaterol may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Olodaterol may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Olodaterol.]
[C03AA02, hydroflumethiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Hydroflumethiazide.]
[G04BD06, propiverine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Olodaterol.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Olodaterol can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Olodaterol may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The metabolism of Olodaterol can be decreased when combined with Ibuprofen.]
[L01DB06, idarubicin, The metabolism of Olodaterol can be decreased when combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Olodaterol can be increased when combined with Ifosfamide.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Sufentanil is combined with Olodaterol.]
[N06AA02, imipramine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Olodaterol.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of hypokalemia can be increased when Tixocortol is combined with Olodaterol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Olodaterol.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Olodaterol.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Olodaterol.]
[C02CA02, indoramin, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Indoramin.]
[N06AX17, milnacipran, Milnacipran may increase the tachycardic activities of Olodaterol.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Piperidolate.]
[A10BH01, sitagliptin, The metabolism of Olodaterol can be decreased when combined with Sitagliptin.]
[N05CH02, ramelteon, The metabolism of Olodaterol can be decreased when combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Olodaterol.]
[G02CX01, atosiban, The risk or severity of adverse effects can be increased when Olodaterol is combined with Atosiban.]
[C10AA06, cerivastatin, The metabolism of Olodaterol can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may decrease the bronchodilatory activities of Olodaterol.]
[C03BA02, quinethazone, Olodaterol may increase the hypokalemic activities of Quinethazone.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Iprindole is combined with Olodaterol.]
[N06AF05, iproniazid, The metabolism of Olodaterol can be decreased when combined with Iproniazid.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Isocarboxazid is combined with Olodaterol.]
[P01AX06, atovaquone, The metabolism of Olodaterol can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, The risk or severity of adverse effects can be increased when Isoetharine is combined with Olodaterol.]
[C09AA16, imidapril, Olodaterol may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Olodaterol.]
[J04AC01, isoniazid, The metabolism of Olodaterol can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Isoprenaline is combined with Olodaterol.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Isoxsuprine is combined with Olodaterol.]
[L04AC07, tocilizumab, The metabolism of Olodaterol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Olodaterol can be decreased when combined with Ketamine.]
[C02KD01, ketanserin, Olodaterol may decrease the antihypertensive activities of Ketanserin.]
[B01AC22, prasugrel, The metabolism of Olodaterol can be decreased when combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Olodaterol can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Olodaterol can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Olodaterol.]
[V03AC03, deferasirox, The metabolism of Olodaterol can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Olodaterol can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Mizolastine.]
[C01CA22, arbutamine, The risk or severity of adverse effects can be increased when Arbutamine is combined with Olodaterol.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Rotigotine is combined with Olodaterol.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Tiaprofenic acid is combined with Olodaterol.]
[C07AG01, labetalol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Olodaterol.]
[C02AA05, deserpidine, Olodaterol may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The metabolism of Olodaterol can be decreased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Etacrynic acid.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Olodaterol can be decreased when combined with Armodafinil.]
[N02CA07, lisuride, Lisuride may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Lofepramine is combined with Olodaterol.]
[A07DA03, loperamide, The metabolism of Olodaterol can be decreased when combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Olodaterol can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Olodaterol.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Olodaterol.]
[C02BB01, mecamylamine, Olodaterol may decrease the antihypertensive activities of Mecamylamine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Olodaterol.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Olodaterol.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Mephentermine is combined with Olodaterol.]
[N03AB04, mephenytoin, The metabolism of Olodaterol can be decreased when combined with Mephenytoin.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Mesoridazine.]
[N05AX13, paliperidone, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Olodaterol.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Methadone.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Metamfetamine is combined with Olodaterol.]
[A03AB07, methantheline, The risk or severity of Tachycardia can be increased when Methantheline is combined with Olodaterol.]
[G02CB05, metergoline, Metergoline may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[H03BB02, methimazole, The metabolism of Olodaterol can be decreased when combined with Methimazole.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Olodaterol.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Methoxyflurane is combined with Olodaterol.]
[C03AA08, methyclothiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Methyclothiazide.]
[C02AB01, methyldopa, Olodaterol may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, The metabolism of Olodaterol can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, Methylergometrine may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[R03DA05, aminophylline, Aminophylline may increase the hyperkalemic activities of Olodaterol.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Olodaterol.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Olodaterol.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Olodaterol.]
[N02CA04, methysergide, Methysergide may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Olodaterol.]
[C03BA08, metolazone, Olodaterol may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Olodaterol.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Mianserin is combined with Olodaterol.]
[S02AA13, miconazole, The metabolism of Olodaterol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Olodaterol can be decreased when combined with Aminophenazone.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Olodaterol.]
[G03XB01, mifepristone, The serum concentration of Olodaterol can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, The metabolism of Olodaterol can be decreased when combined with Valsartan.]
[D11AX01, minoxidil, Olodaterol may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Olodaterol.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Olodaterol.]
[N06AA09, amitriptyline, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Amitriptyline.]
[N02AA01, morphine, The metabolism of Olodaterol can be decreased when combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Olodaterol can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Olodaterol can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Olodaterol.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Olodaterol.]
[G04CA04, silodosin, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Silodosin.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Olodaterol.]
[G03XC01, raloxifene, The metabolism of Olodaterol can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Olodaterol.]
[C07AA12, nadolol, Nadolol may decrease the bronchodilatory activities of Olodaterol.]
[L04AC03, anakinra, The metabolism of Olodaterol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Naphazoline is combined with Olodaterol.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Olodaterol.]
[M02AA12, naproxen, The metabolism of Olodaterol can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Olodaterol can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, Duloxetine may increase the tachycardic activities of Olodaterol.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Remifentanil is combined with Olodaterol.]
[A10BX02, repaglinide, The metabolism of Olodaterol can be decreased when combined with Repaglinide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Levosimendan.]
[N05AX14, iloperidone, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Iloperidone.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the tachycardic activities of Olodaterol.]
[C09CA07, telmisartan, Olodaterol may decrease the antihypertensive activities of Telmisartan.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Nialamide is combined with Olodaterol.]
[C08CA04, nicardipine, The metabolism of Olodaterol can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[P02DA01, niclosamide, The metabolism of Olodaterol can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Olodaterol.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Niflumic acid is combined with Olodaterol.]
[C08CA06, nimodipine, Olodaterol may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Olodaterol may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Olodaterol.]
[C02DD01, nitroprusside, Olodaterol may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Nitrous oxide is combined with Olodaterol.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Olodaterol.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Olodaterol.]
[C02KX01, bosentan, The metabolism of Olodaterol can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Nortriptyline.]
[R05DA07, noscapine, The metabolism of Olodaterol can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Nylidrin is combined with Olodaterol.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olodaterol.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Olodaterol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Olodaterol can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Opipramol is combined with Olodaterol.]
[R03CB03, metaproterenol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Olodaterol.]
[G04CA02, tamsulosin, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Tamsulosin.]
[A14AA08, oxandrolone, The metabolism of Olodaterol can be decreased when combined with Oxandrolone.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Oxprenolol may decrease the bronchodilatory activities of Olodaterol.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Olodaterol is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Olodaterol.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Oxyphenbutazone is combined with Olodaterol.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Olodaterol.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olodaterol.]
[N05AH05, asenapine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Asenapine.]
[M03AC01, pancuronium, The risk or severity of Tachycardia can be increased when Pancuronium is combined with Olodaterol.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Olodaterol.]
[C02KC01, pargyline, Olodaterol may decrease the antihypertensive activities of Pargyline.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Olodaterol.]
[G04BD11, fesoterodine, The risk or severity of Tachycardia can be increased when Fesoterodine is combined with Olodaterol.]
[C07AA23, penbutolol, Penbutolol may decrease the bronchodilatory activities of Olodaterol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Penfluridol.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hyperkalemic activities of Olodaterol.]
[N04BC02, pergolide, Pergolide may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Olodaterol.]
[N02BE03, phenacetin, The metabolism of Olodaterol can be decreased when combined with Phenacetin.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Phenelzine is combined with Olodaterol.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Olodaterol.]
[N03AA02, phenobarbital, The metabolism of Olodaterol can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Olodaterol.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Olodaterol.]
[V03AB36, phentolamine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Phentolamine.]
[M02AA01, phenylbutazone, The metabolism of Olodaterol can be decreased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Olodaterol.]
[R01BA01, phenylpropanolamine, The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Olodaterol.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Olodaterol.]
[L04AB06, golimumab, The metabolism of Olodaterol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Levofloxacin.]
[C08CX01, mibefradil, Olodaterol may decrease the antihypertensive activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Pimozide.]
[C07AA03, pindolol, Pindolol may decrease the bronchodilatory activities of Olodaterol.]
[C10AA05, atorvastatin, The metabolism of Olodaterol can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, The metabolism of Olodaterol can be decreased when combined with Saquinavir.]
[C09CA02, eprosartan, Olodaterol may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Olodaterol.]
[S01BC06, piroxicam, The metabolism of Olodaterol can be decreased when combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Grepafloxacin.]
[N02CX01, pizotyline, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Olodaterol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Olodaterol can be decreased when combined with Irbesartan.]
[D05AX05, tazarotene, The metabolism of Olodaterol can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Olodaterol can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Olodaterol can be decreased when combined with Anastrozole.]
[A03AE01, alosetron, The metabolism of Olodaterol can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Olodaterol can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of hypokalemia can be increased when Olodaterol is combined with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Olodaterol can be decreased when combined with Ritonavir.]
[C10AA08, pitavastatin, The metabolism of Olodaterol can be decreased when combined with Pitavastatin.]
[C07AB01, practolol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Prajmaline.]
[C02CA01, prazosin, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Prazosin.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Olodaterol.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Olodaterol.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Prenylamine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Primaquine.]
[N03AA03, primidone, The metabolism of Olodaterol can be decreased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Olodaterol can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Olodaterol.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Olodaterol.]
[C10AB05, fenofibrate, The metabolism of Olodaterol can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Prochlorperazine.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Procyclidine is combined with Olodaterol.]
[G03DA04, progesterone, The metabolism of Olodaterol can be decreased when combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Olodaterol.]
[C01BC03, propafenone, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Propafenone.]
[A03AB05, propantheline, The risk or severity of Tachycardia can be increased when Propantheline is combined with Olodaterol.]
[N05AC01, periciazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Olodaterol.]
[C07AA05, propranolol, Propranolol may decrease the bronchodilatory activities of Olodaterol.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Rizatriptan is combined with Olodaterol.]
[B01AC09, epoprostenol, Olodaterol may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Olodaterol can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Protriptyline is combined with Olodaterol.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Olodaterol.]
[N05AX12, aripiprazole, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Aripiprazole.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Isopropamide is combined with Olodaterol.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Olodaterol is combined with Methscopolamine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Olodaterol.]
[P01BD01, pyrimethamine, The metabolism of Olodaterol can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Quinine.]
[C02AA01, rescinnamine, Olodaterol may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Olodaterol may decrease the antihypertensive activities of Reserpine.]
[J04AB02, rifampin, The metabolism of Olodaterol can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Olodaterol is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of adverse effects can be increased when Ritodrine is combined with Olodaterol.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Salicylamide is combined with Olodaterol.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Olodaterol.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Olodaterol.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Olodaterol.]
[N05CA06, secobarbital, The metabolism of Olodaterol can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Olodaterol can be decreased when combined with Selegiline.]
[C07AA07, sotalol, Sotalol may decrease the bronchodilatory activities of Olodaterol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Olodaterol.]
[C03DA01, spironolactone, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Spironolactone.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Olodaterol.]
